Have a feature idea you'd love to see implemented?
Let us know!
RVNC Revance Therapeutics Inc
Price (delayed)
$5.26
Market cap
$551.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.2
Enterprise value
$961.28M
Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide
Highlights
Revance Therapeutics's gross profit has soared by 52% YoY and by 7% from the previous quarter
RVNC's revenue is up by 36% YoY and by 4.7% from the previous quarter
Revance Therapeutics's quick ratio has decreased by 37% YoY and by 36% from the previous quarter
Revance Therapeutics's equity has decreased by 31% from the previous quarter
Key stats
What are the main financial stats of RVNC
Market
Valuations
Earnings
Shares outstanding
104.82M
Market cap
$551.37M
Enterprise value
$961.28M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.94
Revenue
$243.9M
EBIT
-$265.77M
EBITDA
-$258.82M
Free cash flow
-$209.22M
Per share
Balance sheet
Liquidity
EPS
-$3.2
Free cash flow per share
-$2.01
Book value per share
-$1.24
Revenue per share
$2.35
TBVPS
$4.68
Total assets
$494.8M
Total liabilities
$624.54M
Debt
$491.64M
Equity
-$129.74M
Working capital
$256.54M
Debt to equity
-3.79
Current ratio
3.74
Quick ratio
2.87
Net debt/EBITDA
-1.58
Margins
Efficiency
Dividend
EBITDA margin
-106.1%
Gross margin
71.5%
Net margin
-117.9%
Operating margin
-112.6%
Return on assets
-57.1%
Return on equity
N/A
Return on invested capital
-34.9%
Return on capital employed
-66.3%
Return on sales
-109%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RVNC stock price
How has the Revance Therapeutics stock price performed over time
Intraday
1.35%
1 week
-2.41%
1 month
-20.18%
1 year
-49.67%
YTD
-40.16%
QTD
1.35%
Financial performance
How have Revance Therapeutics's revenue and profit performed over time
Revenue
$243.9M
Gross profit
$174.47M
Operating income
-$274.59M
Net income
-$287.5M
Gross margin
71.5%
Net margin
-117.9%
Revance Therapeutics's gross profit has soared by 52% YoY and by 7% from the previous quarter
Revance Therapeutics's net margin has increased by 41% YoY and by 13% QoQ
The operating margin is up by 38% year-on-year and by 12% since the previous quarter
RVNC's revenue is up by 36% YoY and by 4.7% from the previous quarter
Growth
What is Revance Therapeutics's growth rate over time
Valuation
What is Revance Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.94
The EPS rose by 31% YoY and by 12% QoQ
Revance Therapeutics's equity has decreased by 31% from the previous quarter
The P/S is 100% lower than the 5-year quarterly average of 486.3 and 21% lower than the last 4 quarters average of 2.8
RVNC's revenue is up by 36% YoY and by 4.7% from the previous quarter
Efficiency
How efficient is Revance Therapeutics business performance
The ROS rose by 42% YoY and by 15% QoQ
The ROIC has grown by 27% YoY and by 13% from the previous quarter
The ROA has increased by 4.8% QoQ and by 2.7% YoY
Dividends
What is RVNC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RVNC.
Financial health
How did Revance Therapeutics financials performed over time
The total assets is 21% less than the total liabilities
Revance Therapeutics's quick ratio has decreased by 37% YoY and by 36% from the previous quarter
The current ratio has contracted by 30% from the previous quarter and by 27% YoY
The debt to equity has dropped by 123% year-on-year but it is up by 21% since the previous quarter
Revance Therapeutics's equity has decreased by 31% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.